Navigation Links
Study Shows Pine Bark Naturally Reduces Osteoarthritis
Date:4/16/2008

ication provided they recorded every tablet in a diary for later evaluation.

To describe and rate osteoarthritis symptoms (joint pain, stiffness and physical function), WOMAC questionnaires were evaluated by the investigator and patient at the start and after three months of treatment. Patients were trained on a treadmill test and performance evaluation was recorded on total distance that could be covered without pain. Measuring foot volume by the water-displacement method was used to evaluate ankle/foot edema in a randomly selected subgroup of subjects within the two treatment groups.

After three months, scores for pain dropped significantly for the Pycnogenol(R) treatment group and no significant effects were recorded for the placebo group. Scores for stiffness were reduced by 53 percent. The scores for physical function were reduced by 57 percent in the Pycnogenol(R) group and improvement under placebo was not significant. The global WOMAC score decreased following Pycnogenol(R) treatment and very little in the placebo group, from 56 percent vs. 9.6 percent for Pycnogenol(R) and placebo, respectively. Overall well-being of patients (emotional function) was significantly enhanced with the Pycnogenol(R) group, by 64 percent and 15 percent for the placebo group.

Results of exercise tests on the treadmill demonstrated an increased performance after three months of Pycnogenol(R) treatment. At the start of the study, patients could only walk a mean of 74 yards without feeling pain and after three months, they could walk 216 yards, compared to the placebo group that noted 71 yards at the beginning of the study and 96 yards at the end.

In addition to the osteoarthritis results, 76 percent of the patients in the Pycnogenol(R) group and 79 percent in the placebo group showed visible ankle and foot edema at inclusion of the study. After the three months, edema decreased in 79 percent of the Pycnogenol(R) patients and only one percent in placebo-t
'/>"/>

SOURCE Natural Health Science Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Study suggests too much screen time and not enough physical activity may lead to childhood obesity
2. St. Jude gene study reveals basis of anticancer drug resistance in childhood leukemia
3. UAB study shows investigational drug may treat biliary cancers
4. Study shows that high-dose, high-frequency interferon produces no additional benefit
5. Study finds media coverage of breast cancer focuses too little on prevention
6. USC study finds evidence of gender-related differences in development of colon cancer
7. New study in JCSM finds that obesity can predict upper airway obstruction amongst children
8. Study shows increase of hip and knee replacements in the US
9. Study shows decline in work disability due to rheumatoid arthritis
10. Study details cost-effectiveness of rheumatoid arthritis treatments for Medicare recipients
11. Study sheds light on deadly lung disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...,s Bed & Back; Merger Sets Up Healthy Back as...ain, LORTON, Va., May 16 /PRNewswire/ -- Healthy ...and workplace back wellness created an,ergonomic r...its rival,JoAnne,s Bed & Back. Healthy Back,s 18 ...s of $40million. JoAnne,s 16 mid-Atlantic stores,c...
(Date:5/16/2008)...wire-USNewswire/ -- This release is,being sent in ...on with the,National Cancer Institute, part of the...he American Society of Clinical,Oncology meeting i...ractice,in about 25 percent of patients with colon...he way colorectal cancers will be staged., * This...
(Date:5/16/2008)...s gain benefit from calcitriol, an oral form , ... activated vitamin D may cut the risk of death for...ease by about one quarter, a new study suggests. ...tients, those being treated with calcitriol, an or...risk of death lowered by 26 percent when compared ...
(Date:5/16/2008)...aise $38 Million for Life-threatening,Disease, BE...kers in nearly,every state will raise funds for cy...participating in GREAT STRIDES, the largest nation...announced today., May is National Cystic Fibrosis...ening genetic disease that causes fatal lung infec...
Breaking Medicine News(10 mins):Health News:The Back Wars Come to a Close 2Health News:New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer 2Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2Health News:GREAT STRIDES Walks for Cystic Fibrosis Slated for 47 States This Weekend 2
... assistants, typically graduate students hired to ... college campuses. Indiana University shyness expe...eople hired to help new students with their conver...become staples, as well. New students, said Cardu...
...trial body recognizing the downward trend of acces...wo things needed to reverse the situation- more mo... According to the Federation of Indian Chambers ...dia needs to spend around $203 billion (Rs 912,37...
...traditional diet of fish, tofu, vegetables and ric...r, but a change of eating habits is weighing down...ry estimates that every second male and every fift...and experts have identified a change in lifestyle ...
...udy has found that what boys lose in the process o...parts of the penis. The long-term-health impact ...y, while the consequences of circumcision on sexua... male have received even less attention. But now,...
Other Medicine News:Health News:Binge Drinking on College Campuses is a Matter of Fear, Not Freedom 2Health News:Binge Drinking on College Campuses is a Matter of Fear, Not Freedom 3Health News:FICCI Proposes Models To Solve Indias Healthcare Crisis 2Health News:Japanese are Weighed Down by Deviating from Their Traditional Diet 2
(Date:5/16/2008)...swire-FirstCall/ -- Memory Pharmaceuticals,Corp. (...ral key development,programs at its R&D Day meetin...ted new clinical data for MEM 1414, its lead PDE4 ...ty in humans. In addition, the,Company has nominat...m its,5-HT6 antagonist program, and separately con...
(Date:5/16/2008)...wire/ -- BioVex Inc, a biotechnology,company devel...ctious,disease, announced today that the abstract ...linical trial of OncoVEX GM-CSF in advanced metast...iety of Clinical Oncology,(ASCO) website located a...,which describes the data as of the submission dat...
(Date:5/16/2008)...rkers -- for Lung Cancer Diagnosis and, Identifica...known Primary (CUP...ith High Sensitivity and, Specificity and Could ...esults of microRNA Signature to Identify Tissue Or...% and Specificity of 99%, REHOVOT, Israel and JER...
(Date:5/16/2008)...cally Significant Reductions in Selected ... be published in 2008 Proceedings of the American ...logy, SAN DIEGO, May 16 /-...unced today that, in a registrational bioequivalen...cally significant reduction,in general disorders a...
Breaking Medicine Technology:Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day 2Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day 3Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day 4BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5Poniard Pharmaceuticals Announces Upcoming Conference Participation 5030 1Poniard Pharmaceuticals Announces Upcoming Conference Participation 5030 2Thermo Fisher Scientific to Host Analyst Meeting 5025 1Thermo Fisher Scientific to Host Analyst Meeting 5025 2MedCath Corporation to Present at the Deutsche Bank Securities 33rd Annual Health Care Conference 18142 1United Therapeutics Reports First Quarter 2008 Financial Results 5024 1United Therapeutics Reports First Quarter 2008 Financial Results 5024 2United Therapeutics Reports First Quarter 2008 Financial Results 5024 3United Therapeutics Reports First Quarter 2008 Financial Results 5024 4United Therapeutics Reports First Quarter 2008 Financial Results 5024 5United Therapeutics Reports First Quarter 2008 Financial Results 5024 6United Therapeutics Reports First Quarter 2008 Financial Results 5024 7
...April 19, 2007 /PRNewswire-FirstCall/ --,VioQuest ...maceutical company focused on acquiring, developin...nnounced data from its,preclinical studies of VQD-... treatment of solid and hematologic tumors.,Pre-cl... 2007,Annual Meeting of the American Association f...
...e Top-Line Phase III Results for,Keppra® as Ad...diatric Patients from One Month to Less than Four ...- UCB today announced,positive top-line results fr...ntre, placebo-controlled study evaluating the,effi...m) (20-50,mg/kg/day) as adjunctive therapy in the ...
Other Medicine Technology:VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 2VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 4VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 5UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 2UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 3UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 4UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 5
Ammonia reagent is used for the quantitative and enzymatic determination of ammonia in human plasma.
The Proteomeworks system is an integrated set of tools and technologies that enables protein function discovery. Innovative new tools for sample preparation, 2-D electrophoresis, staining, imaging an
...e range of concentration, temperature, ionic stren...ion than other methods. Its unique operating metho...ution of molecular weights, providing an efficient...elf-associating systems. The ProteomeLab XL-A/XL-I...
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 1000 mg/dL (11.3 mmol/L). Single vial, dry powder reagent.
Medicine Products: